Borregaard ASA (LON:0QB7)
United Kingdom · Delayed Price · Currency is GBP · Price in NOK | Market Cap | 1.13B -20.2% |
| Revenue (ttm) | 589.74M -0.3% |
| Net Income | 12.86M -80.9% |
| EPS | 0.14 -80.9% |
| Shares Out | n/a |
| PE Ratio | 83.77 |
| Forward PE | 17.64 |
| Dividend | 0.37 (3.25%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 933 |
| Open | 142.00 |
| Previous Close | 141.81 |
| Day's Range | 142.00 - 143.20 |
| 52-Week Range | 138.00 - 200.50 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Borregaard ASA
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as to flavor and fragrance companies, and food and beverage industry. Its BioMaterials segment develops, ... [Read more]
Financial Performance
In 2025, Borregaard ASA's revenue was 7.71 billion, an increase of 1.26% compared to the previous year's 7.62 billion. Earnings were 620.00 million, a decrease of -24.67%.
Financial numbers in NOK Financial StatementsNews
Borregaard ASA Transcript: CMD 2026
Sharpened strategic priorities focus on scaling specialization, productivity, and disciplined capital allocation, with growth driven by high-value applications in BioSolutions and Specialty Cellulose. Financial ambitions target 5% annual revenue growth and a 25% EBITDA margin, supported by selective investments, cost discipline, and a resilient business model.
Borregaard ASA Slides: FY 2026
Borregaard ASA has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 17, 2026.
Borregaard ASA Press release: FY 2026
Borregaard ASA issued a press release on September 17, 2026, disclosing material business information to investors.
Borregaard ASA Slides: Corporate presentation
Borregaard ASA has posted slides in relation to its latest quarterly earnings report, which was published on July 19, 2026.
Borregaard ASA Earnings Call Transcript: Q2 2026
Q2 2026 saw stable EBITDA and revenue growth, with strong segment volumes but margin pressure from higher costs and a NOK 337 million Alginor impairment. Guidance was revised for BioSolutions and BioMaterials, and a NOK 150 million cost savings program was launched.
Borregaard ASA Slides: Q2 2026
Borregaard ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Borregaard ASA Quarterly report: Q2 2026
Borregaard ASA has published its Q2 2026 quarterly earnings report on July 16, 2026.
Borregaard upgraded to Buy from Hold at SEB Equities
SEB Equities upgraded Borregaard (BRRDF) to Buy from Hold with a NOK 165 price target The firm believes the “bad news” is largely behind the company.
Borregaard ASA Transcript: Pre-close call
Sales volumes for key segments are on track, but product mix and cost inflation are pressuring margins. Management is implementing cost controls and sees long-term opportunities despite geopolitical and market uncertainty.
Borregaard ASA: Alginor faces a challenging financial situation
In recent months, Alginor has seen challenges with raw material supply, delayed product development and commercialisation, and additional cost overruns in the demonstration plant investment. As of now...
Borregaard ASA: Initiation of share repurchase programme
8 May 2026: Borregaard ASA ("Borregaard", OSE ticker: BRG) Borregaard intends to repurchase up to 300,000 shares of its outstanding common stock. The shares will be used for employee incentive program...
Borregaard upgraded to Buy from Hold at Danske Bank
Danske Bank analyst Elliott Jones upgraded Borregaard (BRRDF) to Buy from Hold with a NOK 170 price target
Borregaard ASA Earnings Call Transcript: Q1 2026
EBITDA and revenues declined year-over-year due to lower BioSolutions volumes and higher costs, while Fine Chemicals posted strong growth. Geopolitical uncertainty and cost inflation are impacting outlook, but targeted cost measures and a diversified portfolio provide resilience.
Borregaard ASA Quarterly report: Q1 2026
Borregaard ASA has published its Q1 2026 quarterly earnings report on April 29, 2026.
Borregaard ASA Slides: Q1 2026
Borregaard ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Borregaard ASA: EBITDA1 of NOK 428 million in the 1st quarter
Borregaard's operating revenues were NOK 2,005 million (NOK 2,036 million) in the 1st quarter of 2026. EBITDA1 was NOK 428 million (NOK 511 million). The result in Fine Chemicals increased, while BioS...
Borregaard ASA Slides: Corporate presentation
Borregaard ASA has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Borregaard ASA: Shares traded ex-dividend today
The shares in Borregaard ASA will be traded ex-dividend of NOK 4.75 per share as from today, 17 April 2026. Borregaard ASASarpsborg, 17 April 2026 Contact: Lotte Kvinlaug, Investor Relations Officer, ...
Borregaard ASA Transcript: AGM 2026
The AGM approved all proposals, including a 12% higher dividend, board and committee elections, and remuneration adjustments. Financial results showed strong growth, with strategic investments in specialization, sustainability, and capacity expansion. No shareholder objections or questions were raised.
Borregaard upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux analyst Martin Granviken upgraded Borregaard (BRRDF) to Buy from Hold with a price target of NOK 192, down from NOK 194. The firm cites the recent pullback in…
Borregaard ASA Transcript: Pre-close call
Sales volumes are set to rise in both BioSolutions and BioMaterials for 2026, though average prices in BioMaterials will decline due to mix and market pressures. Cost volatility, global conflicts, and competition from Chinese imports remain key risks, while currency impacts and hedging strategies are closely monitored.
Borregaard price target lowered to NOK 175 from NOK 220 at Berenberg
Berenberg lowered the firm’s price target on Borregaard (BRRDF) to NOK 175 from NOK 220 and keeps a Hold rating on the shares.
Borregaard downgraded to Hold from Buy at SEB Equities
SEB Equities downgraded Borregaard (BRRDF) to Hold from Buy with a NOK 200 price target
Borregaard ASA Earnings Call Transcript: Q4 2025
All-time high EBITDA was achieved despite lower bioethanol prices and higher costs, with strong cash flow and improved results in BioSolutions and BioMaterials. The dividend is proposed to increase by 12%, and impairments on bio-based startups and a project delay were recorded.
Borregaard ASA Annual report: Q4 2025
Borregaard ASA has published its Q4 2025 annual report on February 4, 2026.